A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: Trial IND.186

Leukemia and Lymphoma

Volumn 54, Issue 4, 2013, Pages 760-766

  Macdonald, David A ^a   Assouline, Sarit E ^b   Brandwein, Joseph ^c   Kamel Reid, Suzanne ^d   Eisenhauer, Elizabeth A ^e   Couban, Stephen ^a   Caplan, Stephen ^b   Foo, Alison ^e   Walsh, Wendy ^e   Leber, Brian ^f  

^a QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e Queen's Cancer Research Institute   (Canada)

^f JURAVINSKI CANCER CENTRE   (Canada)

Author keywords

Cytarabine; Leukemia; Sorafenib

Indexed keywords

CD135 ANTIGEN; CYTARABINE; SORAFENIB;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; CONSTIPATION; CREATININE CLEARANCE; DIARRHEA; DRUG ERUPTION; ERYTHEMA MULTIFORME; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GROUPS BY AGE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INFECTION; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PETECHIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SEPSIS; SIDE EFFECT; SURVIVAL RATE; SWEATING; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; NIACINAMIDE; PHENYLUREA COMPOUNDS; TREATMENT OUTCOME;

EID: 84879150977     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.737917     Document Type: Article

References (30)

1. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005; 106: 1154-1163.
2. Mayer RJ, Davis RB, Schiff er C A, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994; 331: 896-903.
3. Lowenberg B, Osenkoppele GJ, van Putten W, et al. High dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009; 36: 1235-1248.
4. Goldstone A H, Burnett A K, Wheatley K, et al. A ttempts to improve outcomes in acute myeloid leukemia (AML) in older patients: The results of the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1302-1311.
5. Lowenberg B, Zittoun R, Kerkhofs H, et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65 + years with acute myeloid leukemia: A randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 1989; 7: 1268-1274.
6. Tilly H. Low dose Ara-C versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 1990; 8: 272-279.
7. Burnett AK, Milligan D, Prentice AG, et al. A comparison of lowdose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fi t for intensive treatment. Cancer 2007; 109: 1114-1124.
8. Burnett AK, Mohite U. Treatment of older patients with acute myeloid leukemia-new agents. Semin Hematol 2006; 43: 96-106.
9. Stirewalt DL and Radich JP. The role of FLT3 in hematopoietic malignancy. Nat Rev Cancer 2003: 3: 650-655.
10. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98 :1752-1759.
11. Whitman S P, Archer K J, Feng L, et al. A bsence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: A Cancer and Leukemia Group B study. Cancer Res 2001; 61: 7233-7239.
12. Podar K, Anderson KC. The pathophysiologic role of VEGF in hematological malignancies: Therapeutic implications. Blood 2005; 105: 1383-1395.
13. Schuch G, Machluf M, Bartsch G Jr, et al. In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo. Blood 2002; 100: 4622-4628.
14. Staber PB, Linkesch W, Zauner D, et al. Common alterations in gene expression and increased proliferation in recurrent acute myeloid leukemia. Oncogene 2004; 23: 894-904.
15. Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase 1 clinical-laboratory correlative trial. Blood 2001; 97: 3361-3369.
16. Zimmerman TM, Harlin H, Odenike OM, et al. Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J Clin Oncol 2004; 22: 4816-4822.
17. Wilhelm S, Chien DS. Sorafenib: Preclinical data. Curr Pharm Des 2002; 8: 2255-2257.
18. Wilhelm S M, Carter C, Tang L, et al. Sorafenib exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109.
19. Meng X W, Lee S H, Dai H, et al. Mcl-1 as a buff er for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: A mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. J Biol Chem 2007; 282: 29831-29846.
20. Rahmani M, Davis EM, Bauer C, et al. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves downregulation of Mcl-1 through inhibition of translation. J Biol Chem 2005; 280: 35217-35227.
21. Yu C, Bruzek LM, Meng XW, et al. The role of Mcl-1 in downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 2005; 24: 6861-6869.
22. Hu S, Niu H, Inaba H, et al. A ctivity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. J Natl Cancer Inst 2011; 103: 893-905.
23. Crump M, Hedley D, Kamel-Reid S, et al. A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: A NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. Leuk Lymphoma 2010; 51: 252-260.
24. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
25. Cheson B D, Cassileth P A, Head D R, et al. Report of the National Cancer Institute-sponsored workshop on defi nitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990; 8: 813-819.
26. Cheson B D, Bennett J M, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671-3674.
27. Gale RE, Green C, Allen C, et al. The impact of F LT3 internal tandem duplication level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008; 111: 2776-2784.
28. Pratz KW, Cho E, Karp J, et al. Phase I dose escalation trial of sorafenib as a single agent for adults with relapsed and refractory acute leukemias. J Clin Oncol 2009; 27(15 Suppl.): Abstract 7065.
29. Borthakur G, Kantarjian H, Ravandi F, et al. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica 2011; 96: 62-68.
30. Metzelder S, Wang Y, Wollmer E, et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: Sustained regression before and after allogeneic stem cell transplantation. Blood 2009; 113: 6567-6571.